Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use. The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost. In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC. Market Analysis and Insights: Global Generic Injectables Market The global Generic Injectables market size is projected to reach US$ 37630 million by 2027, from US$ 29580 million in 2020, at a CAGR of 3.5% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Generic Injectables market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Generic Injectables market in terms of revenue. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Generic Injectables market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Generic Injectables market. Global Generic Injectables Scope and Market Size Generic Injectables market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Generic Injectables market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type Small Molecule Large Molecule Segment by Application Oncology Anesthesia Anti-Infectives Parenteral Nutrition Cardiovascular Diseases By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA By Company Hospira (Pfizer Inc.) Fresenius Kabi Sandoz (Novartis) Hikma Pharmaceuticals PLC Dr. Reddy’s Laboratories Ltd Grifols Nichi-Iko Group (Sagent) Teva Pharmaceutical Auromedics Sanofi Gland Pharma Endo International PLC
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Generic Injectables Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Small Molecule 1.2.3 Large Molecule 1.3 Market by Application 1.3.1 Global Generic Injectables Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Oncology 1.3.3 Anesthesia
